Long-term Hepatic and Extra-hepatic Outcomes of Chronic Hepatitis C Patients Post Sofosbuvir-based Interferon-free Treatment (LONGHEAD Study)
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 02 Jul 2019
Price : $35 *
At a glance
- Drugs Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Acronyms LONGHEAD
- 04 Mar 2019 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated
- 28 Feb 2017 Planned number of patients changed from 600 to 200.